Osteoporotic hip fractures: Bisphosphonates sales and observed turning point in trend. A population-based retrospective study

Bone

Volumn 53, Issue 2, 2013, Pages 430-436

  Alves, Sandra Maria ^a,b   Economou, Theodoros ^c   Oliveira, Carla ^a,d,e   Ribeiro, Ana Isabel ^a,d,e   Neves, Nuno ^a,f   Goméz Barrena, Enrique ^g   Pina, Maria Fátima ^a,d,e  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c UNIVERSITY OF EXETER   (United Kingdom)

^d UNIVERSITY OF PORTO   (Portugal)

^e University of Porto   (Portugal)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

^g UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Anti osteoporotic medication; Bisphosphonates; Hip fractures; Osteoporosis; Population studies

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DRUG MARKETING; ETHNIC GROUP; FEMALE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; MALE; POPULATION RESEARCH; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; STANDARD; STANDARDIZED MORTALITY RATIO; TREATMENT OUTCOME; TREND STUDY;

AGED; AGED, 80 AND OVER; DIPHOSPHONATES; FEMALE; HIP FRACTURES; HUMANS; MALE; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES;

EID: 84873288549     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.12.014     Document Type: Article

References (26)

1. Cooper C., Cole Z.A., Holroyd C.R., Earl S.C., Harvey N.C., Dennison E.M., et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 2011, 22:1277-1288.
2. Nikitovic M,WodchisWP, Krahn MD, Cadarette SM. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int in press [Epub ahead of print].
3. Ioannidis G., Flahive J., Pickard L., Papaioannou A., Chapurlat R.D., Saag K.G., et al. Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 2013, 24:59-67.
4. Sorensen H.T., Sabroe S., Olsen J. A framework for evaluation of secondary data sources for epidemiological research. Int J Epidemiol 1996, 25:435-442.
5. Hulley S.B., Cummings S.R., Browner W.S., Grady D.G., Newman T.B. Utilizing existing databases. Designing clinical research 2007, 207-220. Lippincott Williams &Wilkins, Philadelphia. 3rd ed.
6. Gomez-Cabello A., Ara I., Gonzalez-Aguero A., Casajus J.A., Vicente-Rodriguez G. Effects of training on bone mass in older adults: a systematic review. Sports Med 2012, 42:301-325.
7. Eurostat Life expectancy at age 65, by gender 2012.
8. INE Instituto Nacional de Estatística 2012.
9. Korhonen N, Niemi S, Parkkari J, Sievanen H, Palvanen M, Kannus P. Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010. Osteoporos Int in press [Epub ahead of print].
10. Fisher A., Martin J., Srikusalanukul W., Davis M. Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging 2010, 5:355-362.
11. Fisher A.A., O'Brien E.D., Davis M.W. Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 2009, 45:246-253.
12. Hiligsmann M., Bruyere O., Roberfroid D., Dubois C., Parmentier Y., Carton J., et al. Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007). Arthritis Care Res (Hoboken) 2012, 64:744-750.
13. Abrahamsen B., Vestergaard P. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int 2010, 21:373-380.
14. Leslie W.D., Sadatsafavi M., Lix L.M., Azimaee M., Morin S., Metge C.J., et al. Secular decreases in fracture rates 1986-2006 for Manitoba, Canada: a population-based analysis. Osteoporos Int 2011, 22:2137-2143.
15. Adams A.L., Shi J., Takayanagi M., Dell R.M., Funahashi T.T., Jacobsen S.J. Ten-year hip fracture incidence rate trends in a large California population, 1997-2006. Osteoporos Int 2013, 24:373-376.
16. Arias LH, Treceno C, Garcia-Ortega P, Rodriguez-Paredes J, Escudero A, Sainz M, et al. Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study. Eur J Clin Pharmacol in press [Epub ahead of print].
17. ACSS Auditoria da codificação clínica [Clinical codification Audits] 2011.
18. SPR, SPODOM Recomendaçes para o Diagnóstico e Terapêutica da Osteoporose. Acta Reumatol Port 2007, 32:49-59.
19. DGS Tratamento Farmacológico da Osteoporose Pós-menopaúsica. Lisboa 2011.
20. Akesson K. New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ 2003, 81:657-664.
21. Qaseem A., Snow V., Shekelle P., Hopkins R., Forciea M.A., Owens D.K. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008, 149:404-415.
22. Morris J.A., Gardner M.J. Epidemiological studies. Statistics with Confidence 2000, BMJ Books, Bristol. 2nd ed. D.G. Altman, D. Machin, T.N. Bryant, M.J. Gardner (Eds.).
23. Hastie T., Tibshirani R. Generalized additive models for medical research. Stat Methods Med Res 1995, 4.
24. Faraway J.J. Extending the linear model with R: generalized linear, mixed effects and nonparametric regression models 2006, Chapman & Hall/CRC Taylor & Francis Group, Boca Raton.
25. Briot K., Benhamou C.L., Roux C. Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry. J Clin Densitom 2012, 15:176-185.
26. Freemantle N., Cooper C., Diez-Perez A., Gitlin M., Radcliffe H., Shepherd S., et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013, 24:209-217.